Molecular Prognostic Model, Pancreatic Ductal Adenocarcinoma (PDAC), Regulons
Conditions
Brief summary
The first purpose of this study is to reveal the gene regulatory network of pancreatic cancer by analyzing single-cell transcriptome sequencing data and to draw a pancreatic cancer regulator map. In addition, bulk transcriptome sequencing data are combined to construct and verify the genetic prognostic model of pancreatic cancer regulators, providing clinical tools for accurate prognostic stratification and personalized treatment of pancreatic cancer patients. The second purpose of this study is to explore the molecular mechanism by which the key oncogene in the gene prognostic model promotes pancreatic cancer advance. New ideas and scientific basis are provided for finding potential molecular targets for the treatment of pancreatic cancer. Thus, the investigators included a Tissue Microarray (TMA)-based cohort of 68 PDAC patient tissue samples. TMA was obtained from OUTDO BIOTECH (Shanghai, China). The study was approved by the institutional review board, and ethics document number is YB M-05-01.
Interventions
None listed
Sponsors
Tiejun Ying
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Pancreatic ductal adenocarcinoma * With post-operative paraffin specimens
Exclusion criteria
* Other types of pancreatic cancer other than pancreatic ductal adenocarcinoma * Without post-operative paraffin specimens or less than 20% of the paraffin sections contain cancerous tissue
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intensity of immunofluorescence staining | From January 2019 to January 2024 | In this study, 68 pancreatic ductal adenocarcinoma tissues were used to detect the gene expression by multiple immunofluorescence staining |
Countries
China
Outcome results
None listed